Alejandro P Ugalde Selected Research

RNA (Ribonucleic Acid)

11/2022	Autophagy-linked plasma and lysosomal membrane protein PLAC8 is a key host factor for SARS-CoV-2 entry into human cells.
2/2016	Genome-Wide Polyadenylation Maps Reveal Dynamic mRNA 3'-End Formation in the Failing Human Heart.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alejandro P Ugalde Research Topics

Disease

6	Progeria (Hutchinson Gilford Syndrome) 01/2013 - 07/2008
4	Neoplasms (Cancer) 01/2021 - 01/2010
2	Heart Failure 10/2018 - 02/2016
2	Premature Aging 09/2010 - 07/2008
1	COVID-19 11/2022
1	Heart Diseases (Heart Disease) 10/2018
1	Neoplasm Metastasis (Metastasis) 01/2017
1	Carcinoma (Carcinomatosis) 01/2013
1	Laminopathies 12/2011
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2010
1	Arthritis (Polyarthritis) 01/2010
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2010
1	Alopecia (Baldness) 07/2008
1	Lipodystrophy 07/2008

Drug/Important Bio-Agent (IBA)

4	Proteins (Proteins, Gene)FDA Link 01/2021 - 07/2008
4	Metalloproteases (Metalloproteinases)IBA 01/2013 - 07/2008
3	MicroRNAs (MicroRNA)IBA 10/2018 - 06/2011
2	RNA (Ribonucleic Acid)IBA 11/2022 - 02/2016
2	Lamin Type A (Lamin A)IBA 01/2013 - 12/2011
2	prelamin AIBA 01/2013 - 07/2008
1	Leucine (L-Leucine)FDA Link 01/2017
1	CytokinesIBA 01/2017
1	Amino Acids FDA Link 01/2017
1	Messenger RNA (mRNA)IBA 02/2016
1	3' Untranslated Regions (3' UTR)IBA 02/2016
1	ZincIBA 12/2011
1	Insulin (Novolin)FDA Link 12/2010
1	Growth Hormone (Somatotropin)IBA 12/2010
1	Insulin-Like PeptidesIBA 09/2010
1	DisintegrinsIBA 01/2010
1	ThrombospondinsIBA 01/2010
1	Matrix Metalloproteinases (MMPs)IBA 01/2010
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 07/2008

Therapy/Procedure

2	Therapeutics 01/2017 - 01/2013